MARCH 6, 7, 8, 12, 13; APRIL 30; AND MAY 21, 1974 Printed for the use of the Committee on Government Operations 34-974 O U.S. GOVERNMENT PRINTING OFFICE WASHINGTON: 1974 For sale by the Superintendent of Documents, U.S. Government Printing Office KF 27 COMMITTEE ON GOVERNMENT OPERATIONS JACK BROOKS, Texas CHET HOLIFIELD, California, Chairman L. H. FOUNTAIN, North Carolina ROBERT E. JONES, Alabama JOHN E. MOSS, California BENJAMIN S. ROSENTHAL, New York FERNAND J. ST GERMAIN, Rhode Island FLOYD V. HICKS, Washington JOHN CONYERS, JR., Michigan BILL ALEXANDER, Arkansas BELLA S. ABZUG, New York HAROLD D. DONOHUE, Massachusetts CARDISS COLLINS, Illinois ·6663 1974 FRANK HORTON, New York JOEL PRITCHARD, Washington Apter, Julia, M.D., Ph. D., Rush Medical College, Chicago, Ill_ Cooper, Joseph D., Ph. D., professor of political science, Howard Rodgers, William H., Jr., professor of law, Georgetown University Schmidt, Alexander M., M.D., Commissioner, Food and Drug Ad- ministration; accompanied by J. Richard Crout, M.D., Director, Bureau of Drugs; Peter Barton Hutt, Assistant General Counsel; Lloyd B. Tepper, M.D., Associate Commissioner for Science; Barrett Scoville, M.D., Acting Director of the Division of Bureau of Neuropharmacological Projects; and Robert Wetherell, Director, Office of Legislative Services... Wesson, Laurence G., M.D., Jefferson Medical College, Philadelphia, Letters, statements, etc., submitted for the record by- Apter, Julia, M.D., Ph. D., Rush Medical College, Chicago, Ill.: Crout, J. Richard, M.D., Director, Bureau of Drugs, Food and Drug April 25, 1974, letter from Ayerst Laboratories regarding proposed protocols for additional studies of propranolol hydrochloride in 330-331 April 26, 1966, and May 16, 1966, the Upjohn Co. memorandums August 15, 1972, excerpt from the Federal Register regarding legal status of approved labeling for prescription drugs; prescribing Correspondence sent to the Cardiovascular and Renal Committee FDA documents filed in the Supreme Court-- FDA Public Advisory Committees as of December 31, 1973.. 440-441 FDA statement on Ob/Gyn advisory committee meeting April 27, 231-232 383-384 June 3, 1974, letter to Chairman Fountain regarding subcommittee 319-320 |